August 2026– date –
-
Ribo’s Divesiran (SLN124) Significantly Reduces Phlebotomy Frequency and Improves Patient QoL in Polycythemia Vera Phase IIa Trial
MPN Research Foundation Global Overview Divesiran (SLN124) from Ribo is an siRNA therapy designed to increase hepcidin levels, aiming to control erythrocyte overproduction in polycythemia vera (PV). Clinical trial results showed that pat... -
Heart-Specific LNP Delivery for Myocardial Infarction Remains a Challenge: Conventional LNPs Accumulate in Liver, while Novel Lipid Engineering Targets Lungs and Spleen
American Heart Association Journals USA Overview Lipid nanoparticles (LNPs) are clinically validated non-viral vectors for delivering therapeutics like small molecules, mRNA, and siRNA; however, achieving heart-specific drug delivery for... -
Molecular Glue Development Accelerates: Gluetacs and Degron Advance Key Programs in Targeted Protein Degradation
GlobeNewswire Global Overview The field of molecular glues, a powerful targeted protein degradation (TPD) modality, is rapidly expanding with two significant clinical advancements: Gluetacs Therapeutics has initiated a Phase II trial for... -
FDA Grants Accelerated Approval to Nuvalent’s Zidesamtinib (Jideytro) for ROS1-Positive NSCLC, Two Months Ahead of PDUFA Date
FDA USA Overview On July 22, 2026, the FDA approved Nuvalent, Inc.'s zidesamtinib (Jideytro) for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) previously treated with at least one ROS... -
Generative AI Forges Unprecedented Flavor Molecules, Reshaping the Food Industry
Industry Today USA Overview Generative AI has achieved a significant breakthrough in molecular biology, enabling the de novo design of entirely new flavor molecules that do not exist in nature. This sophisticated system analyzes vast che... -
Focused Ultrasound and Microbubbles Temporarily Open Blood-Brain Barrier for Enhanced Brain Drug Delivery
Drug Target Review UK Overview The blood-brain barrier (BBB) obstructs most therapeutic agents from reaching the brain, a major hurdle in treating neurological disorders. Researchers are advancing focused ultrasound (FUS), specifically l... -
Agentic and Generative AI to Revolutionize Cardiovascular Drug Discovery
American Heart Association Journals USA Overview Large Language Models (LLMs) and agentic AI are poised to fundamentally transform cardiovascular disease (CVD) drug development by enhancing target understanding, accelerating novel compou... -
Kymera Therapeutics’ Oral STAT6 Degrader KT-621 Shows Positive Phase 1b Atopic Dermatitis Data, Potential Injectable Alternative
TradingView Global Overview Kymera Therapeutics' lead candidate, KT-621 (an oral STAT6 degrader leveraging targeted protein degradation), demonstrated positive Phase 1b data in atopic dermatitis. Presented at the American Academy of Derm... -
Non-Endocytic Membrane-Translocating Delivery Strategies Bypass Endosomal Barriers for Gene, mRNA, and Protein Therapies
Drug Target Review UK Overview A new review evaluates non-endocytic membrane-translocating delivery strategies designed to circumvent insufficient endosomal escape efficiency, a major hurdle for many next-generation therapeutics. These e... -
FDA Grants Accelerated Approval to Regeneron’s Bispecific Antibody Linvoseltamab (LYNOZYFIC) for Multiple Myeloma
International Myeloma Foundation USA Overview The International Myeloma Foundation reported that LYNOZYFIC (linvoseltamab-gcpt), a BCMA-CD3 bispecific antibody immunotherapy, received accelerated FDA approval in July 2025. This drug targ...
